NKG2D itself is an important mediator of tumor immuno-surveillance, since animals deficient for NKG2D demonstrate a reduced ability to fight prostate carcinoma and B cell lymphoma, but not chemically induced fibrosarcoma (35). This evidence concerns the gene KLRK1 and B-cell non-Hodgkin lymphoma.